In a significant advancement, researchers from the Nanoscience Center (NSC) at the University of Jyväskylä, Finland, have ...

A research team of the Cluster at the Leibniz Institute for Natural Product Research and Infection Biology—Hans Knöll ...

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, but ...

Now, the candidate has failed to match Eylea in a phase 3 trial, leaving the Australian biotech to consider its own future. The drug in question is sozinibercept, an inhibitor of vascular ...

The mystery of a pyramid structure that was found under the sea off the coast of the Azores Islands in 2013 is still puzzling experts who are not certain whether it is human-made. Diocleciano Silva ...

R. China Engineering Laboratory of Chemical Resources Utilization in South Xinjiang of Xinjiang Production and Construction Corps, College of Chemistry and Chemical Engineering, Tarim University, Alar ...

In focused research groups, students and faculty within WPI’s Chemical Engineering Department go beyond the classroom to solve real-world problems, continuing to make discoveries in areas like ...

The World Health Organization (WHO) reports that more than 40% of adults worldwide are overweight or obese — a statistic that has nearly tripled since 1975. 1,2 However, sustainable weight loss ...

The goal is to determine how often this lincRNA molecule is activated in these cancers. They also hope to identify whether these RNA molecules are more common in any particular tumor subgroups ...

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently established that Amgen’s biosimilar Pavblu violates key patents of Eylea. A U.S.

Investing.com -- Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ: REGN) shares fell 1.5% following a U.S. appeals court decision that upheld a previous ruling, effectively denying a stay on ...

The US Court of Ap­peals for the Fed­er­al Cir­cuit on Fri­day ruled against Re­gen­eron in a close­ly-watched patent in­fringe­ment case in­volv­ing the New York biotech’ … ...